开始雄激素剥夺治疗前血清血脂与去势抵抗性前列腺癌及转移风险:SEARCH数据库结果
在SEARCH数据库中302例根治性前列腺切除术后接受雄激素剥夺治疗(ADT)的非转移性前列腺癌男性中,评估ADT前2年内血清血脂与去势抵抗性前列腺癌(CRPC)及转移风险的关系。中位随访67个月,42例发生CRPC、44例发生转移;总胆固醇和低密度脂蛋白与CRPC无关,低高密度脂蛋白(<40 vs ≥40 mg/dl)与CRPC风险呈提示性关联(HR 1.86,95%CI 0.99-3.48),在ADT后持续未用他汀者中关联更强(HR 3.64,95%CI 1.45-9.17),转移结果类似。
要点
- ADT前总胆固醇和低密度脂蛋白与去势抵抗性前列腺癌风险无关。
- 低高密度脂蛋白(<40 vs ≥40 mg/dl)与CRPC风险呈提示性关联(HR 1.86,95%CI 0.99-3.48)。
- ADT后持续未用他汀者中低高密度脂蛋白与CRPC关联更强(HR 3.64,95%CI 1.45-9.17)。
核心结论
- 在开始ADT的非转移性前列腺癌男性中,血清胆固醇与去势抵抗性前列腺癌或转移无关。
- 低高密度脂蛋白与去势抵抗性前列腺癌和转移风险增加呈提示性关联,尤其在从未使用他汀者中。
- 需要进一步研究探索血脂在ADT后前列腺癌进展中的潜在作用。
研究设计与样本
- SEARCH(Shared Equal Access Regional Cancer Hospital)数据库研究,纳入302例根治性前列腺切除术后接受ADT的非转移性前列腺癌男性。
- 纳入者ADT前从未使用他汀,且有ADT前2年内可用的血清血脂数据。
- 采用Cox比例风险模型检验血脂与ADT后去势抵抗性前列腺癌和转移风险的关联,并校正潜在混杂因素。
- 亚组分析限于ADT后仍为非他汀使用者。
主要发现
- ADT后中位随访67个月,42例发生去势抵抗性前列腺癌,44例发生转移。
- 胆固醇升高者接受ADT年份更早、随访更长且ADT后他汀使用率更高。
- 多变量分析中总胆固醇和低密度脂蛋白与去势抵抗性前列腺癌无关。
- 低高密度脂蛋白(<40 vs ≥40 mg/dl)与去势抵抗性前列腺癌风险增加呈提示性关联(HR 1.86,95%CI 0.99-3.48)。
- ADT后持续未用他汀者中该关联更强(HR 3.64,95%CI 1.45-9.17),转移结果与去势抵抗性前列腺癌相似。
关键数值与推荐
- 总胆固醇分组:<200 vs ≥200 mg/dl。
- 低密度脂蛋白分组:<130 vs ≥130 mg/dl。
- 高密度脂蛋白分组:≥40 vs <40 mg/dl。
- 甘油三酯分组:<150 vs ≥150 mg/dl。
局限性
- 原文结论指出需要进一步研究探索血脂在ADT后前列腺癌进展中的潜在作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We tested the association of serum lipid levels prior to androgen deprivation therapy with the risk of castration resistant prostate cancer and metastasis. MATERIALS AND METHODS: We identified 302 men in the SEARCH (Shared Equal Access Regional Cancer Hospital) database who received androgen deprivation therapy after radical prostatectomy for nonmetastatic disease, had never received statins before androgen deprivation therapy and had available serum lipid data within 2 years prior to androgen deprivation therapy. Cox proportional hazards models were used to test associations between total cholesterol (less than 200 vs 200 mg/dl or greater), low density lipoprotein (less than 130 vs 130 mg/dl or greater), high density lipoprotein (40 or greater vs less than 40 mg/dl) and triglycerides (less than 150 vs 150 mg/dl or greater) and the risk of castration resistant prostate cancer and metastasis after androgen deprivation therapy while adjusting for potential confounders. Subanalyses were restricted to men who remained statin nonusers after androgen deprivation therapy. RESULTS: Median followup after androgen deprivation therapy was 67 months. Castration resistant prostate cancer and metastasis developed in 42 and 44 men, respectively. Men with elevated cholesterol received androgen deprivation therapy in an earlier year and had longer followup and a higher rate of statin use after androgen deprivation therapy. On multivariable analysis total cholesterol and low density lipoprotein were unrelated to castration resistant prostate cancer. Low high density lipoprotein (less than 40 vs 40 mg/dl or greater) was suggestively linked to an increased risk of castration resistant prostate cancer (HR 1.86, 95% CI 0.99-3.48). The association was stronger in men who remained statin nonusers after androgen deprivation therapy (HR 3.64, 95% CI 1.45-9.17). Results for metastasis were similar to those for castration resistant prostate cancer. CONCLUSIONS: Among men with nonmetastatic prostate cancer who started androgen deprivation therapy serum cholesterol was unrelated to castration resistant prostate cancer or metastasis. Low high density lipoprotein was suggestively associated with risks of increased castration resistant prostate cancer and metastasis, particularly in statin never users. Further studies are needed to explore a potential role for lipids in prostate cancer progression after androgen deprivation therapy.
引用
- Dambal S, Howard LE, Allott EH, et al. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. J Urol. 2019. PMID: 31430247. doi:10.1097/JU.0000000000000494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。